RxDoctor Payments Data

Josephine Davis, MD

Family Medicine · Sturgis, SDNPI 1255782751

Payments from drug & device makers

$274in general payments, 2019–2025

Across 17 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$58
  • Lilly USA, LLC$33
  • Novo Nordisk$32
  • Amgen$29
  • AstraZeneca$29
  • Johnson & Johnson$28
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$58
Lilly USA, LLC2$33
Novo Nordisk2$32
Amgen2$29
AstraZeneca2$29
Johnson & Johnson2$28
Medtronic1$20
Merck1$19
GSK1$15
Pfizer1$11

How this compares

$274 in reported general payments places this provider in the 55th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$8,373
Medicare patients
83
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AbrysvoRsv Vacc, Pref A And Pref B/Pf137$41,600
OzempicSemaglutide28$35,566
EliquisApixaban32$27,962
MounjaroTirzepatide15$23,482
ShingrixVaricella-Zoster Ge/As01b/Pf94$19,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,366
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,307
Boostrix TdapDiphth,pertuss(Acell),tet Vac54$3,525
Metoprolol Succinate64$1,316
Atorvastatin Calcium180$1,277
Omeprazole123$1,111
Duloxetine Hcl55$1,054
Losartan Potassium98$864
Levothyroxine Sodium81$822
Potassium Chloride43$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerAbrysvo, Eliquis$11$69,562169 claims
GSKShingrix, Trelegy Ellipta, Anoro Ellipta$15$40,534122 claims
Novo NordiskOzempic$32$35,56628 claims
Lilly USA, LLCMounjaro$33$23,48215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Sturgis

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →